- Home
- PULM vs GDTC Comparison
PULM vs GDTC Comparison
Compare PULM & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- GDTC
- Stock Information
- Founded
- PULM 2003
- GDTC 2018
- Country
- PULM United States
- GDTC Singapore
- Employees
- PULM N/A
- GDTC N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- GDTC Health Care
- Exchange
- PULM Nasdaq
- GDTC Nasdaq
- Market Cap
- PULM 20.5M
- GDTC 21.5M
- IPO Year
- PULM N/A
- GDTC 2023
- Fundamental
- Price
- PULM $5.27
- GDTC $1.94
- Analyst Decision
- PULM
- GDTC Buy
- Analyst Count
- PULM 0
- GDTC 1
- Target Price
- PULM N/A
- GDTC $5.00
- AVG Volume (30 Days)
- PULM 11.7K
- GDTC 18.1K
- Earning Date
- PULM 08-12-2025
- GDTC 01-01-0001
- Dividend Yield
- PULM N/A
- GDTC N/A
- EPS Growth
- PULM N/A
- GDTC N/A
- EPS
- PULM N/A
- GDTC N/A
- Revenue
- PULM $1,921,000.00
- GDTC $368,838.00
- Revenue This Year
- PULM N/A
- GDTC $5.37
- Revenue Next Year
- PULM $134.88
- GDTC N/A
- P/E Ratio
- PULM N/A
- GDTC N/A
- Revenue Growth
- PULM N/A
- GDTC N/A
- 52 Week Low
- PULM $1.78
- GDTC $1.20
- 52 Week High
- PULM $10.40
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- PULM 28.72
- GDTC 39.79
- Support Level
- PULM $5.60
- GDTC $1.85
- Resistance Level
- PULM $6.15
- GDTC $2.26
- Average True Range (ATR)
- PULM 0.29
- GDTC 0.11
- MACD
- PULM -0.08
- GDTC -0.02
- Stochastic Oscillator
- PULM 4.29
- GDTC 31.67
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.